Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial

BACKGROUND: Despite the fast establishment of new therapeutic agents in the management of COVID-19 and large-scale vaccination campaigns since the beginning of the SARS-CoV-2 pandemic in early 2020, severe disease courses still represent a threat, especially to patients with risk factors. This indic...

Descripción completa

Detalles Bibliográficos
Autores principales: Boesing, Maria, Abig, Kristin, Brändle, Michael, Brutsche, Martin, Burri, Emanuel, Frye, Björn C., Giezendanner, Stéphanie, Grutters, Jan C., Haas, Philippe, Heisler, Justian, Jaun, Fabienne, Leuppi-Taegtmeyer, Anne B., Lüthi-Corridori, Giorgia, Müller-Quernheim, Joachim, Nüesch, Reto, Pohl, Wolfgang, Rassouli, Frank, Leuppi, Jörg D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486780/
https://www.ncbi.nlm.nih.gov/pubmed/36127739
http://dx.doi.org/10.1186/s13063-022-06723-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486780/
https://www.ncbi.nlm.nih.gov/pubmed/36127739
http://dx.doi.org/10.1186/s13063-022-06723-w

Ejemplares similares